Preparation & Measurement Guide
BPC-157 10mg Dosage Protocol
Preparation, measurement, commonly documented protocol ranges, and storage for a BPC-157 10mg vial.
1. Preparation and Measurement
10mg Vial With 2mL of Diluent
Add 2mL of bacteriostatic water to the 10mg vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.
Preparation
- Draw 2mL of bacteriostatic water using sterile equipment.
- Let the liquid run slowly down the inside wall of the vial.
- Gently swirl until dissolved. Do not shake.
- Label with the preparation date and refrigerate.
Check the calculation with the peptide calculator.
2. Commonly Documented Schedule
Route commonly described: subcutaneous. Frequency: once daily.
| Period | Documented daily amount | Measurement |
|---|---|---|
| Weeks 1-2 | 200mcg once daily | 0.04mL / 4 units |
| Weeks 3-4 | 400mcg once daily | 0.08mL / 8 units |
| Weeks 5-8+ | 600mcg once daily | 0.12mL / 12 units |
One 10mg vial lasts approximately: 50 days at 200mcg, 25 days at 400mcg, or 16 days at 600mcg.
Practical Notes
- The table applies only to a 10mg vial prepared with exactly 2mL.
- Four units is a small measurement; account for the accuracy of the measuring device.
- Record the amount, date, and preparation used.
3. Supplies Needed
- BPC-157 10mg vial.
- 2mL of bacteriostatic water per vial.
- Sterile U-100 syringes.
- Alcohol swabs.
- Sharps container.
4. Storage and Handling
- Keep unopened vials cool, dry, dark, and protected from moisture.
- After preparation, refrigerate at 2-8 degrees C.
- Protect from light and avoid repeated freeze-thaw cycles.
- Do not use material with particles, discoloration, or a damaged seal.
5. Research Context
BPC-157 has been examined mainly in animal and cell studies involving tendon response, fibroblasts, angiogenic signaling, wound models, and gastrointestinal injury. These findings do not establish human efficacy or a clinically validated dose.
BPC-157 is not an approved therapeutic drug. FDA materials note limited human safety information and potential concerns involving immunogenicity, peptide-related impurities, and ingredient characterization.
Primary Research and Regulatory References
- Transected rat Achilles tendon and tendocyte study, Journal of Orthopaedic Research (2003)
- Rat Achilles tendon-to-bone healing study, Journal of Orthopaedic Research (2006)
- Tendon-fibroblast growth-hormone-receptor study, Molecules (2014)
- Wound, endothelial migration, and angiogenesis study (2015)
- VEGFR2 activation and angiogenesis study (2017)
- FDA: BPC-157 compounding and safety concerns